Q

QuidelOrtho

Develops, produces, and markets diagnostic tests

Quality Lead Design Transfer & Tech Transfer Strategy

Full-TimeUpdated on 10/20/2026
$135k - $175k+ Bonus
Expert
Bachelor's, Master's, MBA, PhD
Rochester, NY, USA+1 moreMore locations: Raritan, NJ, USA
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in Life Sciences, Engineering, or a related technical discipline is required.
  • 10+ years of progressive experience in Quality, Compliance, or related fields within the Medical Device, IVD, or Biopharmaceutical industries.
  • Strong understanding of Quality System regulations and standards, including ISO 13485, FDA 21 CFR 820, and IVDR.
  • Strong product and process knowledge relevant to assay development, verification/validation, and manufacturing workflows.
  • Demonstrated success driving Quality and Compliance initiatives that align with business strategy and regulatory expectations.
  • Excellent collaboration, influence, and communication skills across functional and organizational boundaries.
  • Strong analytical and problem-solving skills, with experience using data to drive decision-making and improvement.
  • Commitment to scientific integrity, compliance excellence, and continuous improvement.
  • Expert-level knowledge of Design Transfer and Technology Transfer for IVD assays, including process readiness, scale-up, and transfer of product requirements into manufacturing.
  • Deep understanding of IVD regulatory and quality system requirements, such as ISO 13485, IVDR, FDA QSR, risk management (ISO 14971), and design control principles.
  • Ability to interpret complex regulatory requirements and translate them into actionable design transfer and quality strategies.
  • Demonstrated experience evaluating process capability, process controls, and design outputs to ensure manufacturability and compliance.
Responsibilities
  • Serve as the primary Quality partner to the Technology Transfer team, providing strategic guidance and oversight throughout assay design transfer and tech transfer activities.
  • Lead development and execution of comprehensive design transfer and technology transfer quality strategies that ensure compliant, sustainable product realization.
  • Collaborate with Design Quality, Quality Operations, R&D, and Manufacturing teams to ensure alignment on design transfer deliverables, risk management, and process capability expectations.
  • Provide expert interpretation of applicable global regulatory and quality system requirements (e.g., ISO 13485, IVDR, FDA QSR) as they relate to design transfer, process transfer, verification/validation, and manufacturing readiness.
  • Apply deep product and process knowledge to assess transfer risks, guide process understanding, and ensure adequate controls are defined and implemented during scale-up.
  • Support global audit and inspection activities as a subject matter expert and auditee for design transfer, tech transfer, and related quality system elements.
  • Proactively identify quality gaps, systemic risks, and continuous improvement opportunities within design transfer frameworks and lead cross-functional teams to implement solutions.
  • Mentor engineers and contribute to development of organizational capability in design transfer strategy and regulatory compliance.
  • Perform other work-related duties as assigned.
Desired Qualifications
  • Strong analytical and systems-thinking skills to evaluate end-to-end product realization pathways.
  • Ability to anticipate risks in design transfer and proactively implement mitigation strategies.
  • An advanced degree (MS, PhD, MBA, or equivalent) in a relevant discipline.
  • Experience implementing or optimizing global Quality Management Systems (QMS) and digital tools.
  • Lean Six Sigma, PMP, or similar certification demonstrating process improvement expertise.
  • Experience supporting or leading Health Authority or Notified Body inspections.

About the company

QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1937

Get referred to QuidelOrtho

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LEX launch later in 2026 adds a high-growth point-of-care molecular product.
  • Ex-China revenue grew 6% constant currency in Q2 2026, showing core franchise resilience.
  • Cost actions target $50 million net savings through 2027, supporting margin expansion.

What critics are saying

  • China's IVD pricing guidelines crushed Q2 2026 revenue 23.3% and guide cuts persist.
  • Free cash flow guidance was withdrawn after Q2 2026; deleveraging slips if China worsens.
  • A $2.8 billion debt load and B+ negative outlook leave bankruptcy risk if execution fails.

What makes QuidelOrtho unique

  • QuidelOrtho's LEX VELO, acquired April 2026, delivers PCR results in six minutes.
  • Its immunoassay, molecular, and transfusion platforms span point-of-care through hospital laboratories.
  • VITROS 450 and high-sensitivity troponin broaden a sticky installed base across care settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Employee Assistance Program

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
PR Newswire
Oct 7th, 2026
QuidelOrtho appoints Sanjeev Sharma as VP of investor relations

QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, effective 28 September 2026. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research. Most recently, he served as Senior Director of Investor Relations at Teva Pharmaceuticals. He previously spent more than a decade at Genpact in investor relations and business strategy roles, and nearly six years in sell-side equity research. Sharma holds a master's degree in finance and is a Chartered Financial Analyst. QuidelOrtho is a global provider of diagnostic solutions with expertise spanning clinical chemistry, immunoassay, immunohematology, and molecular testing.

Market Chameleon
Oct 7th, 2026
QuidelOrtho taps a 20-year IR veteran to lead shareholder communications.

QuidelOrtho taps a 20-year IR veteran to lead shareholder communications. 7 October 2026, 11:58 AM Leadership change centers on "sharpening communications" with a newly appointed VP of Investor Relations. QuidelOrtho Corporation (NASDAQ:QDEL) announced the appointment of Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. The company said Sharma brings more than 20 years of experience spanning investor relations, corporate strategy, and equity research at global organizations. In the press release, Chief Financial Officer Micah Young highlighted Sharma's combination of investor relations leadership, healthcare experience, financial expertise, and capital markets perspective, describing it as especially valuable as QuidelOrtho works to "sharpen our communications and deepen our engagement with shareholders and analysts." Sharma's background blends healthcare IR and sell-side research experience. QuidelOrtho pointed to Sharma's most recent role as Senior Director of Investor Relations at Teva Pharmaceuticals, where he worked with senior leadership to communicate strategy and strengthen engagement with the investment community "during a period of significant transformation." Before Teva, he spent more than a decade at Genpact in progressively senior roles across investor relations and business strategy, and earlier in his career he spent nearly six years in sell-side equity research.

Spot On New Jersey
Oct 6th, 2026
Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility.

Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility. RARITAN, N.J. - Another longtime New Jersey business facility is heading for the exits. QuidelOrtho plans to close its 66-acre Route 202 campus in Raritan [...] |!| Raritan

Yahoo Finance
Aug 17th, 2026
QuidelOrtho rallies 31.7% despite China slowdown and slashed 2026 guidance

QuidelOrtho Corporation has risen 31.7% over three months, but faces headwinds that may limit further gains. The diagnostics company reported second-quarter revenues of $630.9 million, up 2.8% year over year, with Labs, Immunohematology and Point of Care segments all posting growth. Excluding China, revenues grew 6% at constant currency. Adjusted EBITDA increased 21% to $129 million, reaching a 20.5% margin, supported by ongoing cost optimisation efforts targeting $50 million in net savings through 2027. However, China revenues fell 23.3% at constant currency due to distributor inventory reductions ahead of pricing changes. Management expects these challenges to persist through 2026. QuidelOrtho lowered its full-year revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and cut adjusted earnings guidance to 65-90 cents per share from $1.80-$2.00, citing China weakness and conservative respiratory season assumptions.

Yahoo Finance
Aug 17th, 2026
QuidelOrtho reports Q2 revenue of $630.9M, stock drops 12% on weak guidance

QuidelOrtho reported second-quarter revenues of $630.9 million, up 2.8% year-over-year and exceeding analyst expectations by 2.1%. The company, formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, develops diagnostic testing solutions for healthcare providers. Chief executive Brian Blaser noted strong performance across core franchises and regions, except China, where proposed IVD pricing guidelines and softer respiratory demand created headwinds. The broader healthcare equipment and supplies sector showed strength in Q2, with 36 tracked stocks beating revenue estimates by 2% on average. However, next quarter's guidance came in 1.7% below consensus. QuidelOrtho's shares fell 12.3% following its earnings announcement, which included weaker full-year guidance than peers. The stock currently trades at $14.31.